{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer%2C+Rectum&page=29", "query": { "condition": "Cancer, Rectum", "page": 29 }, "page_size": 10 }, "pagination": { "page": 29, "page_size": 10, "total_count": 878, "total_pages": 88, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer%2C+Rectum&page=30&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer%2C+Rectum&page=28&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-26T07:59:42.625Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00316914", "title": "Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity Caused By Oxaliplatin in Patients Receiving Combination Chemotherapy for Stage II, Stage III, or Stage IV Colorectal Cancer That Has Been Completely Removed By Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Colorectal Cancer", "Neurotoxicity" ], "interventions": [ { "name": "calcium gluconate", "type": "DRUG" }, { "name": "magnesium sulfate", "type": "DRUG" }, { "name": "placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 104, "start_date": "2006-01", "completion_date": "2012-11", "has_results": true, "last_update_posted_date": "2016-08-11", "last_synced_at": "2026-10-26T07:59:42.625Z", "location_count": 14, "location_summary": "Augusta, Georgia • Des Moines, Iowa • Bismarck, North Dakota + 1 more", "locations": [ { "city": "Augusta", "state": "Georgia" }, { "city": "Des Moines", "state": "Iowa" }, { "city": "Des Moines", "state": "Iowa" }, { "city": "Des Moines", "state": "Iowa" }, { "city": "Des Moines", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT00316914" }, { "nct_id": "NCT00101348", "title": "Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma", "Recurrent Adenoid Cystic Carcinoma of the Oral Cavity", "Recurrent Basal Cell Carcinoma of the Lip", "Recurrent Colon Cancer", "Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity", "Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity", "Recurrent Lymphoepithelioma of the Nasopharynx", "Recurrent Lymphoepithelioma of the Oropharynx", "Recurrent Metastatic Squamous Neck Cancer With Occult Primary", "Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity", "Recurrent Mucoepidermoid Carcinoma of the Oral Cavity", "Recurrent Non-small Cell Lung Cancer", "Recurrent Pancreatic Cancer", "Recurrent Rectal Cancer", "Recurrent Salivary Gland Cancer", "Recurrent Squamous Cell Carcinoma of the Hypopharynx", "Recurrent Squamous Cell Carcinoma of the Larynx", "Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity", "Recurrent Squamous Cell Carcinoma of the Nasopharynx", "Recurrent Squamous Cell Carcinoma of the Oropharynx", "Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Recurrent Verrucous Carcinoma of the Larynx", "Recurrent Verrucous Carcinoma of the Oral Cavity", "Stage III Adenoid Cystic Carcinoma of the Oral Cavity", "Stage III Basal Cell Carcinoma of the Lip", "Stage III Colon Cancer", "Stage III Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity", "Stage III Inverted Papilloma of the Paranasal Sinus and Nasal Cavity", "Stage III Lymphoepithelioma of the Nasopharynx", "Stage III Lymphoepithelioma of the Oropharynx", "Stage III Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity", "Stage III Mucoepidermoid Carcinoma of the Oral Cavity", "Stage III Pancreatic Cancer", "Stage III Rectal Cancer", "Stage III Salivary Gland Cancer", "Stage III Squamous Cell Carcinoma of the Hypopharynx", "Stage III Squamous Cell Carcinoma of the Larynx", "Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage III Squamous Cell Carcinoma of the Nasopharynx", "Stage III Squamous Cell Carcinoma of the Oropharynx", "Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Stage III Verrucous Carcinoma of the Larynx", "Stage III Verrucous Carcinoma of the Oral Cavity", "Stage IIIB Non-small Cell Lung Cancer", "Stage IV Adenoid Cystic Carcinoma of the Oral Cavity", "Stage IV Basal Cell Carcinoma of the Lip", "Stage IV Colon Cancer", "Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity", "Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity", "Stage IV Lymphoepithelioma of the Nasopharynx", "Stage IV Lymphoepithelioma of the Oropharynx", "Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity", "Stage IV Mucoepidermoid Carcinoma of the Oral Cavity", "Stage IV Non-small Cell Lung Cancer", "Stage IV Pancreatic Cancer", "Stage IV Rectal Cancer", "Stage IV Renal Cell Cancer", "Stage IV Salivary Gland Cancer", "Stage IV Squamous Cell Carcinoma of the Hypopharynx", "Stage IV Squamous Cell Carcinoma of the Larynx", "Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage IV Squamous Cell Carcinoma of the Nasopharynx", "Stage IV Squamous Cell Carcinoma of the Oropharynx", "Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Stage IV Verrucous Carcinoma of the Larynx", "Stage IV Verrucous Carcinoma of the Oral Cavity", "Untreated Metastatic Squamous Neck Cancer With Occult Primary" ], "interventions": [ { "name": "erlotinib hydrochloride", "type": "DRUG" }, { "name": "cetuximab", "type": "BIOLOGICAL" }, { "name": "bevacizumab", "type": "BIOLOGICAL" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 66, "start_date": "2005-01", "completion_date": "2008-05", "has_results": false, "last_update_posted_date": "2014-06-11", "last_synced_at": "2026-10-26T07:59:42.625Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00101348" }, { "nct_id": "NCT07458347", "title": "A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "KRAS-mutant Non-small Cell Lung Cancer (NSCLC)", "KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC)", "KRAS-mutant Colorectal Cancer (CRC)", "Other KRAS-mutant Solid Tumors" ], "interventions": [ { "name": "KST-6051", "type": "DRUG" }, { "name": "Gemcitabine/nab-paclitaxel", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "mFOLFOX6", "type": "DRUG" }, { "name": "FOLFIRI", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kestrel Therapeutics, Inc.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 545, "start_date": "2026-04-21", "completion_date": "2029-04", "has_results": false, "last_update_posted_date": "2026-10-15", "last_synced_at": "2026-10-26T07:59:42.625Z", "location_count": 9, "location_summary": "Los Angeles, California • Sarasota, Florida • Tampa, Florida + 6 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT07458347" }, { "nct_id": "NCT01807117", "title": "PET-MRI in Diagnosing Patients With Colon or Rectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Recurrent Colon Cancer", "Recurrent Rectal Cancer", "Stage IIA Colon Cancer", "Stage IIA Rectal Cancer", "Stage IIB Colon Cancer", "Stage IIB Rectal Cancer", "Stage IIC Colon Cancer", "Stage IIC Rectal Cancer", "Stage IIIA Colon Cancer", "Stage IIIA Rectal Cancer", "Stage IIIB Colon Cancer", "Stage IIIB Rectal Cancer", "Stage IIIC Colon Cancer", "Stage IIIC Rectal Cancer", "Stage IVA Colon Cancer", "Stage IVA Rectal Cancer", "Stage IVB Colon Cancer", "Stage IVB Rectal Cancer" ], "interventions": [ { "name": "positron emission tomography", "type": "PROCEDURE" }, { "name": "computed tomography", "type": "PROCEDURE" }, { "name": "magnetic resonance imaging", "type": "PROCEDURE" }, { "name": "fludeoxyglucose F 18", "type": "RADIATION" } ], "intervention_types": [ "PROCEDURE", "RADIATION" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "22 Years", "maximum_age": null, "sex": "ALL", "summary": "22 Years and older" }, "enrollment_count": 15, "start_date": "2013-04", "completion_date": "2014-03-05", "has_results": true, "last_update_posted_date": "2021-05-18", "last_synced_at": "2026-10-26T07:59:42.625Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01807117" }, { "nct_id": "NCT05121948", "title": "A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Squamous Cell Carcinoma of Head and Neck", "Colo-rectal Cancer", "Non Small Cell Lung Cancer", "Transitional Cell Carcinoma of the Bladder", "Other Solid Tumors", "Clear Cell Renal Cell Carcinoma" ], "interventions": [ { "name": "HC-7366", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "HiberCell, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2022-02-23", "completion_date": "2024-03-01", "has_results": false, "last_update_posted_date": "2024-03-08", "last_synced_at": "2026-10-26T07:59:42.625Z", "location_count": 7, "location_summary": "La Jolla, California • Aurora, Colorado • St Louis, Missouri + 3 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT05121948" }, { "nct_id": "NCT02574663", "title": "TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Cancer", "Colorectal Cancer", "Rectal Cancer", "Gastric Cancer", "Esophageal Cancer", "Gastrointestinal Stromal Tumor (GIST)" ], "interventions": [ { "name": "TGR-1202", "type": "DRUG" }, { "name": "nab-paclitaxel + gemcitabine", "type": "DRUG" }, { "name": "Oxaliplatin + Folinic acid + Fluorouracil", "type": "DRUG" }, { "name": "Oxaliplatin + Folinic acid + Fluorouracil + Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "TG Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 66, "start_date": "2015-09-11", "completion_date": "2018-08", "has_results": false, "last_update_posted_date": "2019-10-02", "last_synced_at": "2026-10-26T07:59:42.625Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02574663" }, { "nct_id": "NCT01453452", "title": "S1008: Exercise, Diet, & Counseling in Improving Weight Loss in Overweight Female Breast or Colorectal Cancer Survivors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Anxiety Disorder", "Breast Cancer", "Cognitive/Functional Effects", "Colorectal Cancer", "Depression", "Fatigue", "Pain", "Psychosocial Effects of Cancer and Its Treatment", "Weight Changes" ], "interventions": [ { "name": "behavioral dietary intervention", "type": "BEHAVIORAL" }, { "name": "exercise intervention", "type": "BEHAVIORAL" }, { "name": "counseling intervention", "type": "OTHER" }, { "name": "quality-of-life assessment", "type": "PROCEDURE" } ], "intervention_types": [ "BEHAVIORAL", "OTHER", "PROCEDURE" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "120 Years", "sex": "FEMALE", "summary": "Up to 120 Years · Female only" }, "enrollment_count": 50, "start_date": "2012-03", "completion_date": "2017-01", "has_results": false, "last_update_posted_date": "2020-01-18", "last_synced_at": "2026-10-26T07:59:42.625Z", "location_count": 58, "location_summary": "Tucson, Arizona • Antioch, California • Fremont, California + 45 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Antioch", "state": "California" }, { "city": "Fremont", "state": "California" }, { "city": "Fresno", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01453452" }, { "nct_id": "NCT00021268", "title": "Tocladesine in Treating Patients With Recurrent or Progressive Metastatic Colorectal Cancer", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "tocladesine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": null, "start_date": "2001-04", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-08-02", "last_synced_at": "2026-10-26T07:59:42.625Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00021268" }, { "nct_id": "NCT00003950", "title": "Irinotecan and Cyclosporine in Treating Patients With Metastatic, Advanced or Locally Recurrent Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "cyclosporine", "type": "DRUG" }, { "name": "CPT-11", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2000-01", "completion_date": "2005-01", "has_results": false, "last_update_posted_date": "2014-03-07", "last_synced_at": "2026-10-26T07:59:42.625Z", "location_count": 10, "location_summary": "Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 5 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Decatur", "state": "Illinois" }, { "city": "Evanston", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003950" }, { "nct_id": "NCT07221058", "title": "Adaptive Radiation Boost for Rectal Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Rectum Cancer, Adenocarcinoma" ], "interventions": [ { "name": "Adaptive Radiotherapy Boost", "type": "RADIATION" } ], "intervention_types": [ "RADIATION" ], "sponsor": "Fox Chase Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2025-10-24", "completion_date": "2029-11-01", "has_results": false, "last_update_posted_date": "2025-12-09", "last_synced_at": "2026-10-26T07:59:42.625Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT07221058" } ] }